[Trifluorothymidin-prophylaxis of dendritic keratitis in steroid-treated herpetic keratouveitis (author's transl)].

Abstract

In a randomized double-blind study trifluorothymidine was tested for its ability to prevent dendritic keratitis at a dose of 5 drops daily in patients with steroid-treated herpetic keratouveitis. The corneal epithelium of all 56 patients in the study was free of viral foci prior to initiation of therapy. In the placebo- "protected" group, 6 of 28 patients developed virologically confirmed dendritic keratitis while they were under steroids, whereas all 28 trifluorothymidine-protected patients showed uneventful courses of their steroid regimes. No clinically relevant side-effects of trifluorothymidine prophylaxis were observed in this study.

• Authors: R Sundmacher
• Journal: Klinische Monatsblatter fur Augenheilkunde (Klin Monbl Augenheilkd) Vol. 173 Issue 4 Pg. 516-9 (Oct 1978) ISSN: 0023-2165 [Print] Germany
• Vernacular Title: Trifluorthymidinprophylaxe bei der Steroidtherapie herpetischer Keratouveitiden.
• PMID: 104084 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Ophthalmic Solutions
• Dexamethasone
• Trifluridine
• Thymidine

Topics

• Clinical Trials as Topic
• Dexamethasone (administration & dosage)
• Double-Blind Method
• Drug Evaluation
• Humans
• Keratitis, Dendritic (prevention & control)
• Ophthalmic Solutions
• Thymidine (analogs & derivatives)
• Trifluridine (therapeutic use)
• Uveitis (drug therapy)